Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending February 28, 2016
FDA Expands Combo Drug Indications, Now for more genotypes and transplant patients
Must reads for theWeek ending February 21, 2016
Viral Load Levels in Therapy Determination, Comparing results from 2 assay methods
Children of Mothers With HCV, Studying the rate of transmission
Liver Transplantation in Obese Patients With HCV, Studying odds of receiving transplant and surviving it
HCV Testing in People Living With HIV, Is it routine? Should it be?
HCV/HIV Testing in Routine Primary Care, Assessing the effects
Must reads for theWeek ending February 7, 2016
FDA Approves Zepatier, Indicated for chronic HCV genotypes 1 and 4
HCV Among HIV-positive Men Who Have Sex With Men, Studying prevalence with and without IV drug use
Interferon- and Ribivarin-free Regimens in HCV Treatment, Assessing the effects in older adults
Incident Hepatitis E Infections in Advanced Chronic Hepatitis C, Can it lead to decompensation?
Oral 3-drug combination in HCV, Evaluating response and safety
Must reads for theWeek ending January 17, 2016
HCV Screening in Community Health Centers, Does it meet USPSTF guidelines?
Infectious Complications in HCV After Surgery, Studying patients in surgical intensive care
SAEs in Ribavirin-inclusive HCV Therapies, Assessing their safety
Treating Genotype 1 Chronic HCV, Therapy combines NS5A inhibitor and nucleotide analog polymerase inhibitor
Must reads for theWeek ending December 13, 2015
Protease Inhibitors in Chronic HCV, Overcoming the interferon nonresponse